About AnnJi Pharmaceutical Co. Ltd

Dedicated to New Drug Development in Dermatology & Neurology

Meet Our Board Members

Wendy Huang, Ph.D.

Chair & CEO
AnnJi Pharmaceutical

  • Ph.D. in Toxicology, North Carolina State University
  • Forty years pharmaceutical career across multiple therapeutic areas, medical devices and cosmetic products.
  • Held R&D Leadership and executive positions in multinational companies, including GSK, Stiefel Labs, Connetics Corp., Dermik Laboratories, and Sanofi-Aventis.
  • A strong track record in global product development and organizational development.
  • Lead and contributed to more than 10 market authorizations of new drug products and medical devices.

Jerome Shen, Ph.D.

General Partner/Head of Life Science Investments
Taiwania Capital

  • Ph.D. in Chemical Engineering at the University of Wisconsin, Madison
  • The President and co-founder of Allgenesis Biotherapeutics Inc., a new drug development company addressing the unmet medical needs in the ophthalmology areas since 2014.
  • Before Allgenesis, he was an executive with venture capital firms for 20 years; focusing on investment in the life science and biotech/pharmaceutical industry.
  • He also took the leading roles in several biotech start-ups, responsible for corporate development and strategic initiatives and planning.
  • The Secretary-General of Taiwan Biotech Association, a non-profit organization, from 2005 to 2008.

Calvin Tsai

Director of the Board / CEO of Orient EuroPharma CO., Ltd.

  • Business Administration, University of California, Riverside
  • Director of the Board / CEO of Orient Pharma CO., Ltd.
  • Chairman of OP NanoPharma Co., Ltd.
  • Legal representative person of Babecare Co., Ltd.
  • Director of the Board of Hung Lu Foundation
  • Independent director of Simple Mart Retail Co., Ltd.
  • Pierre Fabre Medicament, UK – Assistant Product Manager
  • Deloitte & Touché – Auditor II
  • Elan Pharmaceutical Co., San Diego – Financial Analyst / Financial Liaison of Sales and Marketing Division

Willy Huang

Project Vice General Manager
Fubon Financial Holding Venture Capital

  • Master Degree in Institute of Microbiology & Immunology, National Yang Ming Chiao Tung University, Taiwan​
  • Project Vice General Manager, Fubon Financial Holding Venture Capital​
  • Sales Representative, Novartis Taiwan Co Ltd.​
  • Manager, China Chemical & Pharmaceutical Co., Ltd.​

Dean Chuang

Director of President International Development Corp.

  • M.S. in Genetics, National Yang-Ming University
  • Over ten years of experience in the biotech/healthcare investments in Taiwan, US, and China. Deeply involved in several licensing deals and M&A transactions.

Michael Huang

Managing Partner
Taiwania Capital

  • MBA, Rice University
  • M.A. in Chemistry, University of Texas, Arlington
  • Prior to joining Taiwania as a Managing Partner, Michael was the co-founder and CEO of NeuroVive Pharmaceutical Asia, Inc. (NVP Asia), a new drug development company focusing on the development of mitochondria-related diseases. During his tenure, NVP Asia had successfully signed out-licensing deals with Sihuan Pharmaceutical and Sanofi Korea.
  • Over 18 years of experience as a venture capitalist, focusing on investments in life science startups in the US, Taiwan, and Japan.
  • Expertized in investing and managing early to late-stage biotech and medical device companies in Greater China, Japan, European and North America regions.

Taiwan’s leading new drug developer in dermatology & neurology

Translation and development of new chemical entities from lead optimization, candidate selection to clinical proof-of-concept

Scroll to Top